Rheumatoid Arthritis - Quest Diagnostics Patient Health Library Rheumatoid Arthritis Medications Medications are usually needed to treat rheumatoid arthritis.
Adalimumab for rheumatoid arthritis - [Medication] - Quest Diagnostics Patient Health Library Adalimumab for rheumatoid arthritis Examples Brand Name Chemical Name Humira adalimumab Adalimumab is given as a shot under the skin (subcutaneous injection).Adalimumab has been approved for use in treating adults with moderate to severe rheumatoid arthritis if at least one other DMARD has failed to slow the disease.
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
cov0345.qxd week 0345 7 Nov 2003 BMS has two applications claiming new pyrrolo- triazine based p38 kinase inhibitors (see page 6) Drug Patenting in Context Supplementary Protection Certificate (SPC) notices this week from the UK Patent Office include two relating to the mid- October entry into force of certificates relating to interferon beta- 1b products.
author: MSparrowhawk
cov0348.qxd week 0348 28 Nov 2003 BMS claims bicyclic modulators of androgen receptor function, having already presented preclinical data on potential prostate cancer candidates at the 226th ACS meeting last September.
author: LEmson
http://www.biosis.org/ts/media/cdjournals/gazettenews/2004/CPG_News_0414.pdf www.current-patents.com ISSN:1464-3499 The records appearing in this Gazette will be added to DOLPHIN, the Database Of alL PHarmaceutical INventions.
PDF cover 0507.qxd DOLPHIN Current Patents Gazette Patenting in Context News & Highlights from Week 0507 The records appearing in this Gazette will be added to DOLPHIN, the database Of all pharmaceutical inventions in the next week.adalimumab was provided.
author: LEmson
PDF cover 0507.qxd page 1
author: LEmson
PDF cover 0513.qxd This weeks UK PDJ reports the grant of an SPC to AHP Manufacturing BV on EP939121 for a recombinant TNF- R p75IgI fusion protein product, such as Etanercept.adalimumab. Humira formulation of adalimumab, which Abbott acquired with Knoll Pharmaceuticals,...
author: LEmson
PDF cover 0513.qxd page 1
author: LEmson
CPG_GazetteCover_0528.qxd DOLPHIN Current Patents Gazette Patenting in Context The UK Patents and Design Journal reports the grant of 4 SPCs this week.adalimumab (Humira) on EP929578, extending...
author: AGregory
CPG_GazetteCover_0528.qxd page 1
author: AGregory
Gazette Weekly Highlights News - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - - Current Patents Gazette - Weekly Highlights News The gazette weekly highlights focuses on patent-related issues making the headlines, on noteworthy new applications, and on litigation and legislation affecting the industry.
BioPortfolio Limited Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook - 1.------ Executive Briefing - 2.------ Introduction - 2.1 --- Definition & Scope - 2.2---- Currently Marketed Monoclonal Antibody Therapeutics - 3.------ Market Size & Growth Rates - 3.1---- Global Market for Monoclonal Antibody Therapeutics - 3.2---- North American Market for Monoclonal Antibody...
CAMBRIDGE ANTIBODY TECHNOLOGY (CAT) GROUP PLC Summary • Major strategic alliance with AstraZeneca in the field of inflammatory diseases: o £75 million subscription in new CAT shares o Alliance operations being established in line with plan • Successful outcome to legal action against Abbott Laboratories in relation to HUMIRA ® royalties: o US$23.73 million back royalties received from Abbott (not...
Emerging treatments for inflammatory bowel disease - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Cambridge Antibody Technology (CAT) Group plc announces first quarter financial results - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
CAMBRIDGE ANTIBODY TECHNOLOGY (CAT) ANNOUNCES FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 30 JUNE 2004 Summary: · ----- Completed enrolment of 236 patients in US clinical trial of Trabio a - · ----- Regulatory approval received to commence a Phase I clinical trial with CAT-354 · ----- Wyeth progressing MYO-029, licensed from CAT, into a Phase I clinical trial · ----- Abbott increased 2004 sales expectations for HUMIRA TM to more than $800 million · -----...
CAMBRIDGE ANTIBODY TECHNOLOGY (CAT)ANNOUNCES PRELIMINARY RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2004 HUMIRA was isolated and optimised by CAT in conjunction with BASF (subsequently acquired by Abbott).adalimumab) is a fully human anti-TNF monoclonal antibody, isolated and optimised by CAT in collaboration with Abbott and approved for marketing as a treatment for rheumatoid arthritis (RA) in over 50 countries.
UK Scientists Deliver on Breakthrough Treatment for Rheumatoid Arthritis Sufferers HUMIRA, also known as adalimumab, was isolated and optimised by Cambridge Antibody Technology (“CAT”), the leading UK biotechnology company - using its patented, world-leading phage display technology - in collaboration with Abbott Laboratories, the US pharmaceutical giant that owns exclusive worldwide rights to the product.HUMIRA was specifically...
Biotech Tracker News - Lymphoma Risk for TNF Inhibitors to 4 p.m EST to hear a safety update on the TNFa inhibitors Humira (adalimumab), Remicade (infliximab), and Enbrel (etanercept).Humira, at least until the relevant risks are better clarified through further investigation.
BioPortfolio Limited 21 Unmet needs 23 CHAPTER 3 CURRENT RA TREATMENTS 27 Medicare analysis 28 Medicare Prescription Drug Improvement and Modernization Act of 2003 (DIMA) 28 DMARD class 32 Enbrel (etanercept) analysis 32 Remicade (infliximab) analysis 36 Kineret (anakinra) analysis 40 Arava (leflunomide) analysis 44 Humira (adalimumab) analysis 47 NSAID class 51 Celebrex (celecoxib) analysis...
BioPortfolio Limited 39 Chapter 2 Erythropoietins 44 Summary 44 Class overview 44 Mechanism of action 46 Global sales 46 Analysis of leading products 47 Procrit/Eprex (epoetin alpha) 47 Epogen (epoetin alpha) and Aranesp (darbepoetin alpha) 50 NeoRecormon/Epogin (epoetin beta) 52 Late stage R&D activity 53 Hemolink (hemoglobin raffimer) 54 Chapter 3 Interferons 56 Summary 56 Class overview 57 Mechanism...
Approved Products_2004.xls 194 Jul- 02 Aranes p hyperglycosylated erythropoietin Chemotherapy- induced anemia Amgen 195 Jul- 02 X yrem Sodium oxybate oral solution Cataplexy associated with narcolepsy Orphan Medical 196 Au g- 02 Prestara Prasterone Lupus Genelabs 197 Se p- 02 Hepsera Adefovir dipivoxil Chronic Hepatitus B Gilead 198 Nov- 02 Mitoz ytrex Generic mitomycin Disseminated adenocarcinoma of the...
author: Reijer
Approved Products_2004.xls page 4
author: Reijer
